2 October 2020
An interim clinical commissioning policy has been in place across the UK since 3 July 2020, defining routine access to remdesivir in the treatment of COVID-19 in adults and children aged 12 years or older. However, due to increased demand against available supply, clinicians are now asked to apply t...
9 September 2020
Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the World Health Organization (WHO) has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease.
19 August 2020
Together with the International Child Health Group, we call on governments, donors and agencies to monitor and report the effects of the pandemic response on families and children, and to prioritise a new era of investment in robust, family-centred health systems.
3 August 2020
Russell has heard from many members with concerns for at-risk and vulnerable children in this period, and we're now seeking your insights. He also welcomes the UK government's recent announcement about obesity and junk food advertising, but we need to understand how people's lives are and see the de...
26 June 2020
Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019, because of fears that they may contain low levels of an impurity called NMDA.
19 May 2020
The Royal College of Paediatrics and Child Health (RCPCH) and Newlife the Charity for Disabled Children are pleased to announce their first joint clinical research fellowship award in childhood disability has been awarded to Dr Asma Soltani at the University of Cambridge. Dr Soltani will research Re...
7 April 2020
Dr Susan Broster has been appointed as our Global Officer, working closely with the staff team and many clinical volunteers to deliver our global child health programmes. Sue replaces Dr Bhanu Williams, who now joins our Board of Trustees.
6 April 2020
Growing up overweight or obese is a pervasive and—importantly—preventable disadvantage. It worsens physical and mental health and reduces social and economic success. It can trap people in a cycle of sedentary activity, overeating, and escalating weight. This leads to poor wellbeing and, ultimately,...
17 March 2020
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
13 March 2020
Russell updates members on how the College is responding to COVID-19. In this message, which has been emailed to all members, he outlines the College's actions towards COVID-19 and highlights advice and guidance for our members.